FDA 483 - Cyrus Caroom, M.D. - May 02, 2025

An FDA inspection of Cyrus Caroom, M.D. in Lubbock, TX, revealed significant deficiencies in the conduct of clinical trials. Observations included failures in obtaining proper informed consent, ensuring adequate IRB review, maintaining complete case histories, and managing investigational drug disposition records. These issues indicate serious non-compliance with regulations governing human subject protection and clinical data integrity.